A Systematic Review and Meta-analysis of the Literature: Chemotherapy and Surgery versus Surgery Alone in Non-small Cell Lung Cancer Sarah Burdett, MSc,

Slides:

Advertisements

Similar presentations

Su K. Metcalfe, MD, MPH, Michael T

Advertisements

Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell.

Volume 383, Issue 9928, Pages (May 2014)

Is Consolidation Chemotherapy after Concurrent Chemo-Radiotherapy Beneficial for Patients with Locally Advanced Non–Small-Cell Lung Cancer?: A Pooled.

Jarrod D. Predina, BA, Matthew M. Puc, MD, Meredith R

Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer: A Real-World Cost-Effectiveness Analysis Ian Cromwell, MSc, Kimberly.

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies Sai-Hong Ignatius Ou, MD,

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Lymphovascular Invasion as a Prognostic Indicator in Stage I Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis Nathan M. Mollberg, DO,

Chee Khoon Lee, PhD, Johnathan Man, M. B. B. S

Quantitative Analysis of Circulating Cell-Free DNA for Correlation with Lung Cancer Survival: A Systematic Review and Meta-Analysis Sarah Cargnin, PhD,

Perioperative versus Preoperative Chemotherapy with Surgery in Patients with Resectable Squamous Cell Carcinoma of Esophagus Yang Zhao, MD, ZhiJun Dai,

Endosonography Versus Mediastinoscopy in Mediastinal Staging of Lung Cancer: Systematic Review and Meta-Analysis Inderpaul Singh Sehgal, MD, DM, Sahajal.

Is Consolidation Chemotherapy after Concurrent Chemo-Radiotherapy Beneficial for Patients with Locally Advanced Non–Small-Cell Lung Cancer?: A Pooled.

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy

ERCC2/XPD Lys751Gln and Asp312Asn Gene Polymorphism and Lung Cancer Risk: A Meta-Analysis Involving 22 Case–Control Studies Ping Zhan, MD, Qin Wang,

The Effectiveness of Postoperative Radiotherapy in Patients With Completely Resected Thymoma: A Meta-Analysis Dong Zhou, MD, Xu-Feng Deng, MD, Quan-Xing.

Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901 Stephen L. Graziano,

The Use of Systemic Treatment in the Maintenance of Patients with Non–Small Cell Lung Cancer: A Systematic Review Swati Kulkarni, MD, Emily T. Vella,

Complement and Correction for Meta-Analysis of Patients with Extensive-Stage Small Cell Lung Cancer Managed with Irinotecan/Cisplatin versus Etoposide/Cisplatin.

Volume 375, Issue 9722, Pages (April 2010)

NA Journal of Thoracic Oncology

Adjuvant Cisplatin and Vinorelbine for Completely Resected Non-small Cell Lung Cancer: Subgroup Analysis of the Lung Adjuvant Cisplatin Evaluation Jean-Yves.

Lymph Node Ratio May Predict the Benefit of Postoperative Radiotherapy in Non– Small-Cell Lung Cancer Damien Urban, MBBS, B Med Sc, Jair Bar, MD, PhD,

PTPRF Expression as a Potential Prognostic/Predictive Marker for Treatment with Erlotinib in Non-Small-Cell Lung Cancer Denis Soulières, MD, Fred R.

The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer Peter Goldstraw, MB, FRCS, John J. Crowley, PhD

A Pharmacogenomic Study of Docetaxel and Gemcitabine for the Initial Treatment of Advanced Non-Small Cell Lung Cancer W Jeffrey Petty, MD, Sommer N.

Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD

Should Patients with Extrapulmonary Small-Cell Carcinoma Receive Prophylactic Cranial Irradiation? Jarushka Naidoo, MB BcH BAO, MRCPI, Min Yuen Teo,

Jarrod D. Predina, BA, Matthew M. Puc, MD, Meredith R

Phase II Trial of Paclitaxel and Cisplatin in Patients with Extensive Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Trial 9430 Thomas E.

Patterns of survival and recurrence after surgical treatment of early stage non–small cell lung carcinoma in the ACOSOG Z0030 (ALLIANCE) trial Stacey.

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Survival Benefit of Neoadjuvant Chemotherapy in Non-small Cell Lung Cancer: An Updated Meta-Analysis of 13 Randomized Control Trials Wei-An Song, MD,

Single-Agent Versus Combination Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2: Prognostic Factors and.

An Updated Meta-Analysis of Randomized Controlled Trials Comparing Irinotecan/Platinum with Etoposide/Platinum in Patients with Previously Untreated.

Second-line or Subsequent Systemic Therapy for Recurrent or Progressive Non-Small Cell Lung Cancer: A Systematic Review and Practice Guideline J Noble,

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

Biostatistics Primer: What a Clinician Ought to Know: Hazard Ratios

A Systematic Analysis of Efficacy of Second-Line Chemotherapy in Sensitive and Refractory Small-Cell Lung Cancer Taofeek K. Owonikoko, MD, Madhusmita.

A systematic review and meta-analysis of stereotactic body radiation therapy versus surgery for patients with non–small cell lung cancer Christopher.

Impact on Disease-Free Survival of Adjuvant Erlotinib or Gefitinib in Patients with Resected Lung Adenocarcinomas that Harbor EGFR Mutations Yelena Y.

Chemotherapy in Patients ≥80 with Advanced Non-small Cell Lung Cancer: Combined Results from SWOG 0027 and LUN 6 Paul J. Hesketh, MD, Rogerio C. Lilenbaum,

Re-evaluation of the Role of Postoperative Radiotherapy and the Impact of Radiation Dose for Non–Small-Cell Lung Cancer Using the National Cancer Database

PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered? Steven G. Gray, PhD Journal of Thoracic.

Treatment Outcomes of Different Prognostic Groups of Patients on Cancer and Leukemia Group B Trial 39801: Induction Chemotherapy Followed by Chemoradiotherapy.

Volume 383, Issue 9928, Pages (May 2014)

Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta- analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in.

A Meta-Analysis of Postoperative Radiotherapy for Thymic Carcinoma

Preoperative versus Postoperative Chemotherapy in Patients with Resectable Non- small Cell Lung Cancer: Systematic Review and Indirect Comparison Meta-Analysis.

DHA-Paclitaxel (Taxoprexin) as First-Line Treatment in Patients with Stage IIIB or IV Non-small Cell Lung Cancer: Report of a Phase II Open-Label Multicenter.

Pathologic Complete Response to Preoperative Chemotherapy Predicts Cure in Early- Stage Non–Small-Cell Lung Cancer: Combined Analysis of Two IFCT Randomized.

Gemcitabine in Brief versus Prolonged Low-Dose Infusion, both Combined with Cisplatin, for Advanced Non-small Cell Lung Cancer: A Randomized Phase II.

A Systematic Review and Meta-analysis of the Literature: Chemotherapy and Surgery versus Surgery Alone in Non-small Cell Lung Cancer Sarah Burdett, MSc,

Immune-Modulating Vaccines in Non-small Cell Lung Cancer

Maintenance Therapy and Advanced Non–Small-Cell Lung Cancer: A Skeptic's View Martin J. Edelman, MD, Thierry Le Chevalier, MD, Jean-Charles Soria, MD,

Recursive Partitioning Analysis Groups II–III Brain Metastases of Non-small Cell Lung Cancer: A Phase II Randomized Study Comparing Two Concurrent Chemoradiotherapy.

Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis Sarah Burdett, Liselotte M. Boevé,

A Phase II Study of Carboplatin, Etoposide, and Exisulind in Patients with Extensive Small Cell Lung Cancer: CALGB 30104 Ramaswamy Govindan, MD, Xiaofei.

Tivantinib in Combination with Erlotinib versus Erlotinib Alone for EGFR-Mutant NSCLC: An Exploratory Analysis of the Phase 3 MARQUEE Study Giorgio V.

Stage I Non-small Cell Lung Cancer: Results for Surgery in a Patterns-of-Care Study in Sydney and for High-Dose Concurrent End-Phase Boost Accelerated.

Efficacy and Safety of Cisplatin/Pemetrexed Versus Cisplatin/Gemcitabine as First-Line Treatment in East Asian Patients with Advanced Non-small Cell Lung.

Gentamicin collagen sponges for the prevention of sternal wound infection: A meta- analysis of randomized controlled trials Michael N. Mavros, MD, Pantelis.

Surveillance Epidemiology and End Results Evaluation of the Role of Surgery for Stage I Small Cell Lung Cancer James B. Yu, MD, Roy H. Decker, MD, PhD,

A Randomized, Phase II Trial of Two Dose Levels of Temsirolimus (CCI-779) in Patients with Extensive-Stage Small-Cell Lung Cancer Who Have Responding.

Concurrent Chemotherapy and Short Course Radiotherapy in Patients with Stage IIIA to IIIB Non-small Cell Lung Cancer Not Eligible for Radical Treatment:

A Review of First-Line Treatment for Small-cell Lung Cancer

Razvan Diaconescu, MD, Chantal Lafond, MD, Renaud Whittom, MD

Kristin A. Higgins, MD, Junzo P. Chino, MD, Neal Ready, MD, Mark W

Presentation transcript:

A Systematic Review and Meta-analysis of the Literature: Chemotherapy and Surgery versus Surgery Alone in Non-small Cell Lung Cancer Sarah Burdett, MSc, Lesley A. Stewart, PhD, Larysa Rydzewska, BSc Journal of Thoracic Oncology Volume 1, Issue 7, Pages 611-621 (September 2006) DOI: 10.1016/S1556-0864(15)30371-3 Copyright © 2006 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Results of searches for RCTs. Journal of Thoracic Oncology 2006 1, 611-621DOI: (10.1016/S1556-0864(15)30371-3) Copyright © 2006 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Hazard ratio plot for overall survival. Each individual trial is represented by a square, the center of which denotes the hazard ratio for that trial. The extremities of the horizontal bars denote the 99% CIs and the inner bars mark the 95% CIs. The size of the square is directly proportional to the amount of information in the trial. The filled diamond at the bottom of the plot gives an overall hazard ratio for the combined results of all trials. The center of the diamond denotes the hazard ratio for all trials and the extremities the 95% CIs. Trials are ordered chronologically by the age of the trial, with the oldest listed first. Journal of Thoracic Oncology 2006 1, 611-621DOI: (10.1016/S1556-0864(15)30371-3) Copyright © 2006 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 Hazard ratio plot for sensitivity analysis for overall survival. Journal of Thoracic Oncology 2006 1, 611-621DOI: (10.1016/S1556-0864(15)30371-3) Copyright © 2006 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 4 Hazard ratio plot for overall survival by chemotherapy grouping. Journal of Thoracic Oncology 2006 1, 611-621DOI: (10.1016/S1556-0864(15)30371-3) Copyright © 2006 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 5 Hazard ratio plot for overall survival by postoperative treatment. Journal of Thoracic Oncology 2006 1, 611-621DOI: (10.1016/S1556-0864(15)30371-3) Copyright © 2006 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 6 Hazard ratio plot for disease-free survival. Journal of Thoracic Oncology 2006 1, 611-621DOI: (10.1016/S1556-0864(15)30371-3) Copyright © 2006 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 7 Begg's and Egger's tests for publication bias. Journal of Thoracic Oncology 2006 1, 611-621DOI: (10.1016/S1556-0864(15)30371-3) Copyright © 2006 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 8 Begg's graph for publication bias. Journal of Thoracic Oncology 2006 1, 611-621DOI: (10.1016/S1556-0864(15)30371-3) Copyright © 2006 International Association for the Study of Lung Cancer Terms and Conditions